A new drug for one of the deadliest cancers nearly doubled patient survival in a major clinical trial. The drug, daraxonrasib, developed by Revolution Medicines, targets a genetic mutation called...
|
|
|
|
 |
|
The Kind of Publication You’ve Been Waiting For
In a world where partisan and biased reporting has become commonplace, you can always count on The Epoch Times for a refreshing dose of factual, honest journalism without spin. When you don’t feel like reading the news, pick up a daily tip from us. From what to do with potentially harmful byproducts in your coffee to how screen time can affect your different organs, our health coverage is deep and extensive. You will find meaningful changes to make right away. Yet what makes you truly love The Epoch Times may be none of the above. It is our talks on art, culture, and history that move hearts. At nighttime or on an indolent Sunday afternoon, find yourself indulging in a fascinating read on stories you have been longing for: Pearl Harbor through the eyes of a navy salvage diver, the sparkly stories behind the stolen Louvre jewels, every reason why you should throw a party… The list is endless. The inspiration is infinite.
Explore our entire treasure trove of content as much as you like for $.25 a week.
|
| Subscribe Now |
| |
|
| WHAT'S HAPPENING |
|
|
|
|
|
|
|
|
|
|
|
| Copyright © 2026 The Epoch Times, All rights reserved. |
|
| The Epoch Times, 129 West 29th Street, Fl 8, New York, NY 10001 | Contact Us |
|
* When sharing an article, giftaccess@TheEpochTimes.com is added to the list of recipients. If your friend is not already a subscriber, we will send them a special link for free access to the article.
Epoch Newsroom delivers big stories to your inbox as soon as they break. Manage your email preferences here or unsubscribe from Epoch Newsroom here.
|
|
|
0 Response to "New Probable Treatment Option for Pancreatic Cancer"